SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen
September 14, 2022 11:22 ET | Sermonix Pharmaceuticals Inc.
Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah Case was reported during Phase 2 study investigating efficacy of lasofoxifene, Sermonix’s...
Breast Cancer Society of Canada Grants $250,000 To Precision Oncology Research at Dalhousie University
June 15, 2022 10:32 ET | The Breast Cancer Society of Canada
SARNIA, Ontario, June 15, 2022 (GLOBE NEWSWIRE) -- The Breast Cancer Society of Canada (BCSC) today announced $250,000 in funding to the Department of Biochemistry and Molecular Biology, Faculty of...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions
June 08, 2022 10:00 ET | Sermonix Pharmaceuticals Inc.
Guiding Researchers and Advocates to Scientific Partnerships (GRASP) launched in 2019 to unite patient advocates, physicians and researchers through meaningful discussions of cancer-related...
Breast Cancer Society of Canada Grants $350,000 To Precision Oncology Research
May 25, 2022 09:24 ET | The Breast Cancer Society of Canada
SARNIA, Ontario, May 25, 2022 (GLOBE NEWSWIRE) -- The Breast Cancer Society of Canada (BCSC) today announced the recipients of their first-ever Breast Cancer Research request for proposals....
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Announces Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 28, 2022 12:47 ET | Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, April 28, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium
December 13, 2021 10:00 ET | Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Dress for the Cause this October for Life Saving Breast Cancer Research
September 14, 2021 13:00 ET | The Breast Cancer Society of Canada
SARNIA, Ontario, Sept. 14, 2021 (GLOBE NEWSWIRE) -- The Breast Cancer Society of Canada (BCSC) today announced its annual Dress for the Cause campaign as well as the addition of their new ‘Pin Your...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Preclinical Lasofoxifene Study in Endocrine-Resistant Breast Cancer
May 17, 2021 10:19 ET | Sermonix Pharmaceuticals LLC
Paper highlights the ability of lasofoxifene to inhibit primary tumor growth and reduce metastases in mouse models, both as monotherapy and in combination with palbociclibStudy results demonstrate...
Join the One Billion Steps Challenge and STEP UP for Breast Cancer Research
March 30, 2021 10:00 ET | The Breast Cancer Society of Canada
SARNIA, Ontario, March 30, 2021 (GLOBE NEWSWIRE) -- The Breast Cancer Society of Canada (BCSC) announced today the 30th anniversary of their annual Mother’s Day Walk, now the One Billion Steps...
Dress Up Your Life This October For Breast Cancer Research, Presented by Cleo
September 08, 2020 14:00 ET | The Breast Cancer Society of Canada
SARNIA, Ontario, Sept. 08, 2020 (GLOBE NEWSWIRE) -- The Breast Cancer Society of Canada (BCSC) announced today their 2020 Dress for the Cause campaign. During the month of October, Breast Cancer...